<< Pediatric Herpes Simplex Virus Infections: An Evidence-Based Approach To Treatment



Prior to the use of antiviral therapy, 85% of neonates with disseminated HSV disease and 50% of neonates with CNS disease died within 12 months of diagnosis.31 Vidarabine (Vira-A®) was the first antiviral medication licensed for use in neonatal HSV. A randomized controlled trial published in 1991 comparing vidarabine with acyclovir found no difference in morbidity or mortality between patients treated with either drug.26

To read the rest of this section, choose one of the options below.

Already purchased this course?
Log in to read.
Purchase a subscription

Price: $449/year

140+ Credits!

Money-back Guarantee
Get Quick-Read Evidence-Based Updates
Enter your email to get free evidence-based content delivered to your inbox once per month.
Please provide a valid email address.